Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Droxidopa (Primary) ; Carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions
- 22 Feb 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2018 Planned End Date changed from 1 Aug 2018 to 31 Dec 2018.